|Dr. James Garner M.A., MBA, MBBS, B.Sc (Hons), SAFin.||Chief Exec. Officer, MD & Exec. Director||193.25k||N/A||44|
|Ms. Gabrielle Heaton BBUS (ACC), CPA||Director of Fin. and Admin.||N/A||N/A||N/A|
|Kym Robins||Director of Marketing & Communications||N/A||N/A||N/A|
|Dr. Peng Leong MBA, Ph.D.||Chief Bus. Officer||N/A||N/A||N/A|
|Dr. Gordon Hirsch MBA, MBBCh, FCP(SA), BSc Hons||Chief Medical Officer||N/A||N/A||N/A|
Novogen Limited engages in the pharmaceutical research and development business in Australia. The company primarily has two drug technology platforms, which include superbenzopyran (SBPs) and anti-tropomyosin (ATMs). Its SBP technology platform offers Cantrixil, an intra-cavity anti-cancer agent for the treatment of ovarian cancer, malignant ascites, and malignant pleural effusion; and Trilexium for the treatment of brain cancers, neuroblastoma, and melanoma. Its ATM technology platform provides Anisina that destructs cancer cells cytoskeleton. The company is also developing various programs in the areas of regenerative medicine, facioscapulohumeral muscular dystrophy, and lysosomal storage disorder. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.
Novogen Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.